Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/BCAR3_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BCAR3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BCAR3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BCAR3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BCAR3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001810510 | Oral cavity | OSCC | peptidyl-serine phosphorylation | 164/7305 | 315/18723 | 1.51e-06 | 1.99e-05 | 164 |
GO:004343419 | Oral cavity | OSCC | response to peptide hormone | 208/7305 | 414/18723 | 1.83e-06 | 2.35e-05 | 208 |
GO:003286816 | Oral cavity | OSCC | response to insulin | 138/7305 | 264/18723 | 7.54e-06 | 8.15e-05 | 138 |
GO:19011847 | Oral cavity | OSCC | regulation of ERBB signaling pathway | 50/7305 | 79/18723 | 1.06e-05 | 1.12e-04 | 50 |
GO:00420587 | Oral cavity | OSCC | regulation of epidermal growth factor receptor signaling pathway | 46/7305 | 73/18723 | 2.80e-05 | 2.59e-04 | 46 |
GO:00082868 | Oral cavity | OSCC | insulin receptor signaling pathway | 67/7305 | 116/18723 | 3.23e-05 | 2.91e-04 | 67 |
GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
GO:00062753 | Oral cavity | OSCC | regulation of DNA replication | 62/7305 | 107/18723 | 5.49e-05 | 4.54e-04 | 62 |
GO:004308710 | Oral cavity | OSCC | regulation of GTPase activity | 165/7305 | 348/18723 | 7.94e-04 | 4.27e-03 | 165 |
GO:00331354 | Oral cavity | OSCC | regulation of peptidyl-serine phosphorylation | 72/7305 | 144/18723 | 4.66e-03 | 1.87e-02 | 72 |
GO:0033138 | Oral cavity | OSCC | positive regulation of peptidyl-serine phosphorylation | 55/7305 | 108/18723 | 7.75e-03 | 2.84e-02 | 55 |
GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
GO:00457405 | Oral cavity | OSCC | positive regulation of DNA replication | 23/7305 | 40/18723 | 1.36e-02 | 4.50e-02 | 23 |
GO:001810514 | Oral cavity | EOLP | peptidyl-serine phosphorylation | 84/2218 | 315/18723 | 3.32e-13 | 1.05e-10 | 84 |
GO:001820914 | Oral cavity | EOLP | peptidyl-serine modification | 87/2218 | 338/18723 | 1.07e-12 | 2.46e-10 | 87 |
GO:190165323 | Oral cavity | EOLP | cellular response to peptide | 85/2218 | 359/18723 | 2.06e-10 | 2.06e-08 | 85 |
GO:004343424 | Oral cavity | EOLP | response to peptide hormone | 89/2218 | 414/18723 | 1.29e-08 | 6.11e-07 | 89 |
GO:003286922 | Oral cavity | EOLP | cellular response to insulin stimulus | 53/2218 | 203/18723 | 1.65e-08 | 7.43e-07 | 53 |
GO:007137523 | Oral cavity | EOLP | cellular response to peptide hormone stimulus | 68/2218 | 290/18723 | 1.98e-08 | 8.62e-07 | 68 |
GO:003286823 | Oral cavity | EOLP | response to insulin | 62/2218 | 264/18723 | 7.78e-08 | 2.76e-06 | 62 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BCAR3 | SNV | Missense_Mutation | | c.382G>A | p.Asp128Asn | p.D128N | O75815 | protein_coding | deleterious(0.01) | possibly_damaging(0.881) | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
BCAR3 | SNV | Missense_Mutation | | c.538C>A | p.Leu180Met | p.L180M | O75815 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A2-A0D2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
BCAR3 | SNV | Missense_Mutation | | c.13N>C | p.Lys5Gln | p.K5Q | O75815 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.82) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BCAR3 | SNV | Missense_Mutation | | c.1987G>A | p.Glu663Lys | p.E663K | O75815 | protein_coding | deleterious(0) | possibly_damaging(0.714) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
BCAR3 | SNV | Missense_Mutation | novel | c.587N>G | p.Ala196Gly | p.A196G | O75815 | protein_coding | tolerated(0.1) | benign(0.297) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
BCAR3 | SNV | Missense_Mutation | | c.1428G>C | p.Leu476Phe | p.L476F | O75815 | protein_coding | deleterious(0.03) | benign(0.116) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
BCAR3 | SNV | Missense_Mutation | novel | c.193G>A | p.Asp65Asn | p.D65N | O75815 | protein_coding | tolerated(0.09) | benign(0.439) | TCGA-D8-A3Z5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
BCAR3 | SNV | Missense_Mutation | novel | c.1246N>T | p.Pro416Ser | p.P416S | O75815 | protein_coding | tolerated(0.16) | benign(0.012) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
BCAR3 | insertion | Frame_Shift_Ins | novel | c.1975_1976insAGTGCCCTGTTTCTCCTTGTGTG | p.Ile659LysfsTer12 | p.I659Kfs*12 | O75815 | protein_coding | | | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BCAR3 | deletion | Frame_Shift_Del | novel | c.409delG | p.Glu137SerfsTer8 | p.E137Sfs*8 | O75815 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |